Cytokinetics Inc/ US23282W6057 /
2024-05-10 10:00:00 PM | Chg. -1.9200 | Volume | Bid12:55:59 AM | Ask12:55:59 AM | High | Low |
---|---|---|---|---|---|---|
62.1000USD | -3.00% | 1.34 mill. Turnover: 57.98 mill. |
61.0000Bid Size: 100 | 62.1000Ask Size: 100 | 64.6100 | 61.2500 |
GlobeNewswire
05-08
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population ...
GlobeNewswire
04-29
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-...
GlobeNewswire
04-10
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at t...
GlobeNewswire
04-05
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Stu...
GlobeNewswire
04-05
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Stu...
GlobeNewswire
04-01
Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire
03-25
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual...
GlobeNewswire
02-29
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
GlobeNewswire
02-28
Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase E...
GlobeNewswire
02-06
Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GlobeNewswire
01-29
Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program